Selection of Non Apoptotic Human Sperm for in Vitro Fertilization by Using Magnetic Activated Cell Sorting (MACS) (MACS-HS)
Evaluation of Embryo Quality After Enrichment of Non-apoptotic Spermatozoa Using Magnetic-activated Cell Sorting (MACS): Study on Sibling Oocytes.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Studies of infertile couples have demonstrated that male factor plays a role in infertility. Spermatozoa can present damages at molecular levels that have an effect on fertilization and embryo development. One of these molecular damages is represented by DeoxyriboNucleic Acid (DNA) fragmentation whose negative impact on embryological outcome appears during genome activation after fertilization and is also correlated with increased miscarriage rate.
DNA fragmentation represents one of the late manifestations of apoptosis. Identification of spermatozoa showing DNA fragmentation (apoptotic spermatozoa) requires fixation and staining. Therefore this method cannot be applied in clinical practice to select for non-apoptotic spermatozoa for ICSI. However, this selection is possible by using magnetic-activated cell sorting (MACS). The procedure is based on the identification and depletion of spermatozoa showing the early marker of apoptosis, namely the externalization of phosphatidylserine (PS), by using the ability of Annexin V to recognize this antigen in the plasma membrane of apoptotic sperm cells. After MACS, the fraction that is enriched in non-apoptotic cells (Annexin V-negative cells) can be further used for clinical application.
The MACS system makes use of a separation column placed in a magnetic field, and of Annexin-V reagent labeled with paramagnetic beads.
Initially, the semen sample will be subject to Density Gradient Centrifugation (DGC). The sample obtained will be divided in 2 fractions: one fraction will be subject to magnetic sorting (fraction 1) and the other fraction will represent the control (no sorting; fraction 2).
The cells from fraction 1 will be incubated with Annexin-V and then passed through the separation column located in a magnetic field. The apoptotic cells (Annexin V-positive cells) will be selectively retained in the column. The non-apoptotic cells, not being labeled by Annexin V, will pass through the column and will be collected for further use.
At the moment of ICSI, sibling mature oocytes will be inseminated with spermatozoa from fraction 1 (enriched in non-apoptotic cells) or from fraction 2 (control, conventionally prepared spermatozoa). Following ICSI, all the inseminated oocytes will be individually cultured in the same conditions in the same culture dish. The choice of embryo(s) for transfer will be based on embryo quality. The supernumerary good-quality embryos from both arms will be frozen for further use.
The present study aims to determine whether the use of MACS improves the embryo quality/utilization rate in couples with high sperm DNA fragmentation rate. To avoid inter-patient variation, the study is design as a sibling oocyte study. Descriptive statistics will be performed by analysing median, mean, proportions, standard deviation, ranges and 95% confidence intervals as appropriate. Standard parametric and non-parametric tests will be used, as appropriate, to compare primary and secondary outcomes between groups. Sample size calculation: a number of 142 mature oocytes in each arm will be necessary to achieve 80% power of detecting, as significant at the 5% level, an increase in the primary outcome measure from 13% in the control group to 26% in the experimental group.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
10.2 Inclusion Criteria
Patients with poor embryo quality in the previous cycles:
- Cycles with no embryo transfer due to insufficient embryo quality
- "Freeze all" cycles without cryopreservation
- Cycles with transfer of embryos with fair and/or poor quality
- Previous diagnostic semen analysis with minimum 30% DNA fragmentation
- ICSI cycles with fresh ejaculated semen with ≥1 mil spermatozoa after DGC.
- Minimum 6 mature oocytes after oocyte pick up.
10.3 Exclusion Criteria
- Cycles with frozen semen sample
- Cycles with testicular sample
- In vitro fertilization (IVF) cycles
- Cycles with pre-implantation genetic diagnosis
- In vitro maturation cycles
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Control group
Half of the mature oocytes of the same patient will be injected with sperm obtained after DGC only (conventionally semen preparation).
|
|
|
Study group
Half of the mature oocytes of the same patient will be injected with sperm obtained after DGC and MACS. The sperm used in this group is considered to be enriched in non apoptotic cells. |
At the moment of ICSI, sibling mature oocytes will be inseminated with spermatozoa from Study group or from Control group.
Following ICSI, all the inseminated oocytes will be individually cultured in the same conditions in the same culture dish.
The choice of embryo(s) for transfer will be based on embryo quality.
The supernumerary good-quality embryos from both arms will be frozen for further use.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
utilization rate
Time Frame: 2 years
|
number of transferred and cryopreserved embryos per mature oocytes
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
fertilization rate
Time Frame: 2 years
|
number of fertilized oocytes per number of injected oocytes
|
2 years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2018-183
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.